Rigel CMO reports vesting of performance stock options

Rigel Pharmaceuticals EVP and Chief Medical Officer Lisa Rojkjaer reported the vesting of previously granted performance-based stock options.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Rigel Pharmaceuticals EVP and Chief Medical Officer Lisa Rojkjaer reported the vesting of previously granted performance-based stock options. On June 17, 2026, performance metrics were determined to be met for options covering 9,375 shares at an exercise price of $14.90 and 7,394 shares at $22.49.

Both option grants became fully vested on June 17, 2026. The 9,375-share grant was originally made on March 27, 2024 and adjusted for a one-for-ten reverse stock split effective June 27, 2024, while the 7,394-share grant was made on January 29, 2025.

Insider Trade Summary

Grant/Award: 16,769 shares

Grant/Award 2 txns

Insider Rojkjaer Lisa

Role EVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	9,375	$0.00	$0.00
Grant/Award	Employee Stock Option (right to buy)	7,394	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 16,769 contracts (Direct)

Footnotes (4)

F1. The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
F2. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
F3. The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
F4. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

Key Figures

Performance options grant 1: 9,375 options Exercise price grant 1: $14.90 per share Performance options grant 2: 7,394 options +4 more

7 metrics

Performance options grant 1 9,375 options Performance-based grant originally dated March 27, 2024

Exercise price grant 1 $14.90 per share Closing price on grant date, adjusted for reverse split

Performance options grant 2 7,394 options Performance-based grant dated January 29, 2025

Exercise price grant 2 $22.49 per share Closing price on Nasdaq on grant date

Vesting date June 17, 2026 Date performance metrics were determined met and options fully vested

Expiration date grant 1 March 27, 2034 Option expiration for 9,375-share grant

Expiration date grant 2 January 29, 2035 Option expiration for 7,394-share grant

Key Terms

performance-based condition, one-for-ten reverse stock split, Section 16, closing price, +1 more

5 terms

performance-based condition financial

"was granted a stock option with a performance-based condition with respect to 9,375 shares"

one-for-ten reverse stock split financial

"as adjusted for the one-for-ten reverse stock split effective June 27, 2024"

Section 16 regulatory

"this grant was not reportable under Section 16 until the performance metric was satisfied"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

closing price financial

"The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock"

fully vested financial

"The option was fully vested on June 17, 2026, the date the determination was made"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RIGL EVP CMO Lisa Rojkjaer report?

Lisa Rojkjaer reported the vesting of two performance-based stock option grants. On June 17, 2026, performance metrics were determined to be met, causing both option awards to become fully vested and reportable under Section 16 as derivative acquisitions.

How many Rigel (RIGL) shares are covered by Lisa Rojkjaer’s vested options?

The vested performance-based options cover 9,375 shares in one grant and 7,394 shares in another. Each option represents the right to buy common stock, giving total option coverage of 16,769 shares across the two awards once fully vested.

What are the exercise prices of Lisa Rojkjaer’s Rigel performance options?

One option grant has an exercise price of $14.90 per share, and the other has an exercise price of $22.49 per share. Both prices reflect the closing price of Rigel’s common stock on Nasdaq on their respective grant dates.

When were the Rigel (RIGL) performance-based options originally granted?

The 9,375-share performance-based option was granted on March 27, 2024 and later adjusted for a one-for-ten reverse stock split. The 7,394-share performance-based option was granted on January 29, 2025, both subject to performance conditions before vesting.

Why were these Rigel stock option grants reported on June 17, 2026?

Both grants were subject to performance-based vesting conditions and were not reportable under Section 16 until those metrics were satisfied. On June 17, 2026, the company determined that the performance metrics had been met, making the options fully vested and reportable.

Are Lisa Rojkjaer’s Rigel performance-based options fully vested now?

Yes. The filing states that each performance-based option grant was fully vested on June 17, 2026. This vesting date coincides with the determination that the applicable performance metrics had been met for both awards, converting them into fully vested options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 04:11 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rojkjaer Lisa

(Last)

(First)

(Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$14.9⁽¹⁾	06/17/2026		A		9,375⁽¹⁾		⁽²⁾	03/27/2034	Common Stock	9,375⁽¹⁾	$0	9,375	D
Employee Stock Option (right to buy)	$22.49⁽³⁾	06/17/2026		A		7,394⁽³⁾		⁽⁴⁾	01/29/2035	Common Stock	7,394⁽³⁾	$0	7,394	D

Explanation of Responses:

1. The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

2. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

3. The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

4. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

	/s/ Raymond Furey (Attorney-in-Fact)	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR